全文获取类型
收费全文 | 184570篇 |
免费 | 15138篇 |
国内免费 | 5697篇 |
专业分类
耳鼻咽喉 | 2040篇 |
儿科学 | 3555篇 |
妇产科学 | 2570篇 |
基础医学 | 13889篇 |
口腔科学 | 3763篇 |
临床医学 | 21031篇 |
内科学 | 26714篇 |
皮肤病学 | 3427篇 |
神经病学 | 9653篇 |
特种医学 | 6841篇 |
外国民族医学 | 54篇 |
外科学 | 16919篇 |
综合类 | 28175篇 |
现状与发展 | 26篇 |
一般理论 | 3篇 |
预防医学 | 11063篇 |
眼科学 | 2929篇 |
药学 | 14876篇 |
121篇 | |
中国医学 | 14859篇 |
肿瘤学 | 22897篇 |
出版年
2024年 | 364篇 |
2023年 | 3040篇 |
2022年 | 5364篇 |
2021年 | 7774篇 |
2020年 | 7306篇 |
2019年 | 6371篇 |
2018年 | 6362篇 |
2017年 | 6768篇 |
2016年 | 7366篇 |
2015年 | 6962篇 |
2014年 | 12993篇 |
2013年 | 15630篇 |
2012年 | 11200篇 |
2011年 | 11930篇 |
2010年 | 9733篇 |
2009年 | 8964篇 |
2008年 | 8959篇 |
2007年 | 9489篇 |
2006年 | 8590篇 |
2005年 | 7752篇 |
2004年 | 6290篇 |
2003年 | 5820篇 |
2002年 | 4610篇 |
2001年 | 4144篇 |
2000年 | 3462篇 |
1999年 | 2793篇 |
1998年 | 2222篇 |
1997年 | 1932篇 |
1996年 | 1550篇 |
1995年 | 1396篇 |
1994年 | 1107篇 |
1993年 | 866篇 |
1992年 | 746篇 |
1991年 | 681篇 |
1990年 | 598篇 |
1989年 | 525篇 |
1988年 | 479篇 |
1987年 | 413篇 |
1986年 | 341篇 |
1985年 | 443篇 |
1984年 | 374篇 |
1983年 | 290篇 |
1982年 | 290篇 |
1981年 | 245篇 |
1980年 | 235篇 |
1979年 | 178篇 |
1978年 | 120篇 |
1977年 | 81篇 |
1976年 | 81篇 |
1975年 | 49篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
141.
142.
Takashi Murakami Naoto Sakamoto Akihito Nagahara 《Journal of gastroenterology and hepatology》2019,34(10):1685-1695
Sessile serrated adenoma/polyps (SSA/Ps) are early precursor lesions in the serrated neoplasia pathway, which results in BRAF‐mutated colorectal carcinomas with not only high levels of microsatellite instability but also microsatellite stable. SSA/Ps with advanced histology, including cytological dysplasia or minimally invasive carcinomas, are important lesions because SSA/Ps are considered major contributors to “interval cancers” and these lesions can rapidly become dysplastic or invasive carcinomas. Clinicopathologically, SSA/Ps with dysplasia or invasive carcinoma were associated with advanced age, female sex, and proximal colon. Although SSA/Ps with submucosal invasive carcinoma were smaller and invaded less deeply into the submucosal layer than conventional tubular adenomas with submucosal invasive carcinoma, SSA/Ps with submucosal invasive carcinoma frequently had a mucinous component and exhibited a higher potential for lymphatic invasion and lymph node metastasis. In an SSA/P series, endoscopic characteristics, including (semi)pedunculated morphology, double elevation, central depression, and reddishness, may help accurately diagnose SSA/Ps with advanced histology. Removal of SSA/Ps with dysplasia or invasive carcinoma was recommended. Endoscopic treatment such as endoscopic mucosal resection or endoscopic submucosal dissection is useful for those lesions. However, surgical resection with lymph node dissection might be indicated when SSA/Ps with invasive carcinoma are endoscopically suspected, because these have the high risk of lymph node metastasis. Greater awareness may promote further research into improving the detection, recognition, and complete resection rates of SSA/Ps with dysplasia or invasive carcinoma and reduce the interval cancer rates. 相似文献
143.
目的探讨自血穴位注射疗法联合马来酸茚达特罗治疗老年稳定期慢性阻塞性肺疾病(COPD)的临床疗效及其对患者炎性因子、免疫功能及肺功能的影响。 方法将2015年5月至2016年5月我院收治的86例老年缓解期COPD患者分为观察组与对照组。对照组给予马来酸茚达特罗治疗,观察组在对照组治疗基础上另给予自血穴位注射疗法。治疗12周后,评价2组临床疗效。治疗前及治疗12周后,分别检测2组患者肺功能指标(FEV1、FVC与PEF),炎性因子(IL-8、α1-AT、IL-6及TNF-α),免疫功能指标(IgG、IgA、CD3+及CD4+)水平。治疗期间,对2组患者的不良反应进行密切观察。 结果治疗后二组患者各项检测指标均优于治疗前。治疗12周后,观察组总有效率为90.7%,明显高于对照组的72.1%(P<0.05)。治疗12周后,观察组FEV1、FVC与PEF等肺功能指标,IgG、IgA、CD3+及CD4+等免疫功能指标水平均明显高于对照组(P<0.05),而IL-8、α1-AT、IL-6及TNF-α含量分别为(23.23±3.87)ng/L、(3.43±0.41)g/L、(52.25±5.38)ng/L及(43.12±3.98)ng/L,改善程度均明显优于对照组(P<0.05)。治疗期间,2组患者均未出现严重不良反应。 结论自血穴位注射疗法联合马来酸茚达特罗治疗老年稳定期COPD疗效确切,可有效改善患者炎症水平,值得进行深入研究。 相似文献
144.
145.
146.
《Clinical Lymphoma, Myeloma & Leukemia》2020,20(8):e461-e467
IntroductionVon Willebrand factor (vWF) cleaving protease ADAMTS-13 has a key role for maintaining normal size of vWF. A deficiency or dysfunction of vWF cleaving protease is associated with ultra large vWF multimers and thrombotic microangiopathy. Patients with cancers have reduced levels of vWF cleaving protease. In this pilot study, we have evaluated whether or not deficiencies of ADAMTS-13 were present in myelodysplastic syndromes (MDS). Moreover, we assessed if a reduction in basal levels of ADAMTS-13 may play a role in the prognosis of MDS.Patients and MethodsWe measured and compared the levels of vWF cleaving protease ADAMTS-13 in 100 patients with MDS and 35 healthy controls. Patients were divided into 2 groups according to the International Prognostic Scoring System: group I consisting of 44 patients with low-risk MDS and group II of 56 patients with high-risk MDS. Patients with high-risk and low-risk MDS presented significantly lower levels of ADAMTS-13 than controls (P < .001 and P = .0177, respectively). High-risk patients had significantly lower levels of ADAMTS-13 when compared with the low-risk group (P < .001).ResultsWe found that reduced levels of ADAMTS-13 have a relationship with overall survival (P < .001). Statistical analysis showed that ADAMTS-13 correlates with cytogenetics (P < .001) and a tendency of slight correlation with platelet count and basal levels of ADAMTS-13 (R, 0.35; P value, 0.001). Moreover, we found that levels of ADAMTS-13 have correlation with response to treatment (P < .001).ConclusionsADAMTS-13 in MDS might represent a surrogate marker of prognosis, response to therapy, or disease progression. Further studies are needed. 相似文献
147.
148.
149.
150.
Altan Ahmed John A. Stauffer Jordan D. LeGout Justin Burns Kristopher Croome Ricardo Paz-Fumagalli Gregory Frey Beau Toskich 《Journal of gastrointestinal oncology.》2021,12(2):751
BackgroundNeoadjuvant yttrium-90 transarterial radioembolization (TARE) is increasingly being used as a strategy to facilitate resection of otherwise unresectable tumors due to its ability to generate both tumor response and remnant liver hypertrophy. Perioperative outcomes after the use of neoadjuvant lobar TARE remain underinvestigated.MethodsA single center retrospective review of patients who underwent lobar TARE prior to major hepatectomy for primary or metastatic liver cancer between 2007 and 2018 was conducted. Baseline demographics, radioembolization parameters, pre- and post-radioembolization volumetrics, intra-operative surgical data, adverse events, and post-operative outcomes were analyzed.ResultsTwenty-six patients underwent major hepatectomy after neoadjuvant lobar TARE. The mean age was 58.3 years (17–88 years). 62% of patients (n=16) had primary liver malignancies while the remainder had metastatic disease. Liver resection included right hepatectomy or trisegmentectomy, left or extended left hepatectomy, and sectorectomy/segmentectomy in 77% (n=20), 8% (n=2), and 15% (n=4) of patients, respectively. The mean length of stay was 8.3 days (range, 3–33 days) and there were no grade IV morbidities or 90-day mortalities. The incidence of post hepatectomy liver failure (PHLF) was 3.8% (n=1). The median time to progression after resection was 4.5 months (range, 3.3–10 months). Twenty-three percent (n=6) of patients had no recurrence. The median survival was 28.9 months (range, 16.9–46.8 months) from major hepatectomy and 37.6 months (range, 25.2–53.1 months) from TARE.ConclusionsMajor hepatectomy after neoadjuvant lobar radioembolization is safe with a low incidence of PHLF. 相似文献